Public Meeting for Patient-Focused Drug Development on Opioid Use Disorder (OUD) | National Institute on Drug Abuse (NIDA)

Public Meeting for Patient-Focused Drug Development on Opioid Use Disorder (OUD) | National Institute on Drug Abuse (NIDA)

Public Meeting for Patient-Focused Drug Development on Opioid Use Disorder (OUD)

Details

April 17, 2018 - 10:00am to 4:00pm

FDA, Silver Spring, Maryland

Web site

Contact

United States Food and Drug Administration

Additional Information

On April 17, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Opioid Use Disorder (OUD), in collaboration with National Institute of Drug Abuse (NIDA). In addition to NIDA, FDA is also working closely with patient advocacy and community organizations to encourage participation from individuals with OUD. This meeting aligns with FDA’s ongoing work aimed at reducing the impact of opioid abuse and addiction.

In particular, FDA is interested in learning patients’ perspectives on OUD, including the effects on their health and well-being that have the greatest impact on daily life, their experience using prescription medical treatments and other treatments or therapies for OUD, and challenges or barriers to accessing or using medical treatments for OUD.